Sartorius Viral Vectors Platform
Single-Use Technologies and Associated Services to Address the Process Development and Productions Needs of Manufacturers of Viral Vectors
Sartorius technologies are ideally suited for the production of viral vaccines, vectors and gene therapies. They allow end-to-end, single-use processing of viruses from process development through to commercial manufacturing at the 2000 L-scale. Manufacturers of virus-related products are benefiting from our unique upstream and downstream technologies, analytics and services including our process development consultancy, cost modelling and process engineering capabilities.
Recombinant viral vectors are used in a growing number of vaccine applications, and bring new perspective in the prevention of infectious diseases. The use of viral vectors enable intracellular antigen expression and illicit a strong immune response in patients. They also allow a platform approach for various vaccine indications.
The growing number of viral vectors used as clinical therapeutics will require scalable commercial upstream and downstream processes to be developed and optimized to ensure that critical quality attributes (CQAs) are retained.
Take a Look at ABL Europe’s New Production Facility for the GMP Manufacture of Viral Vectors from Non-Adherent Cell Cultures – Supported by Sartorius Stedim Biotech
“Our new state-of-the-art viral vector productions suite contains a single-use, fully disposable production line. [...] Sartorius delivered the project exactly on-time and according to our expectations. It all ran very smoothly and we received good support during qualification.”
Patrick Mahieux, General Manager of ABL.